Cross-Sector entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Aparna Thakur, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Atrasentan (VANRAFIA), all published on July 27, 2026.
1 verified story tracked
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Aparna Thakur, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Atrasentan (VANRAFIA), all published on July 27, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Atrasentan (VANRAFIA). Shared-story counts are live from our verified record — not editorial picks.
A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Source: prnewswire.com · finanznachrichten.de
